Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345441 | 0.90 | CHRNA7 (0.50) | CYP19A1GRIN2BGRIN1HTR2CCHRNA7 | |
| SCHEMBL3069878 | 0.88 | CHRNA7 (0.49) | CYP19A1GRIN2BGRIN1LMNAHSD17B10 | |
| SCHEMBL1744785 | 0.87 | PGR (0.48) | CYP19A1GRIN2BGRIN1LMNAHSD17B10 | |
| SCHEMBL326892 | 0.86 | MTNR1A (0.54) | CYP19A1DRD2DRD3HTR2C | |
| SCHEMBL20341744 | 0.82 | FFAR1 (0.52) | GRIN2B | |
| SCHEMBL18094372 | 0.82 | FFAR1 (0.52) | GRIN2B | |
| SCHEMBL629387 | 0.81 | HTR2C (0.50) | CYP19A1LMNAHSD17B10SRD5A1DRD2 | |
| SCHEMBL9403350 | 0.81 | OPRM1 (0.56) | LMNAESR1 | |
| SCHEMBL4140163 | 0.80 | LMNA (0.50) | CYP19A1LMNAHSD17B10SRD5A1DRD2 | |
| SCHEMBL9749057 | 0.80 | LMNA (0.50) | CYP19A1LMNAHSD17B10SRD5A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2024-12-10 | — | — | US | disclosed |
| WO-2024162284-A1 | PYRAZOLE-4-CARBOXAMIDE COMPOUND AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT USING SAME | クミアイ化学工業株式会社 | 2024-08-08 | — | — | WO | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| EP-3946299-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | Taiwanj Pharmaceuticals Co., Ltd. (TW) | 2022-02-09 | — | — | EP | disclosed |
| CN-113660932-A | Phenyl derivatives with pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020205455-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS, CO., LTD. (TW) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020205455-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS, CO., LTD. (TW) | 2020-10-08 | — | — | WO | disclosed |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-02-27 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN ING. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-3987082-A | PROSTAGLANDIN INTERMEDIATE | MERCK & CO., INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3987082-A | PROSTAGLANDIN INTERMEDIATE | MERCK & CO., INC. (US) | 1976-10-19 | — | — | US | disclosed |
| US-3950359-A | PROSTAGLANDINS AND METHODS OF MAKING SAME | MERCK & CO., INC. (US) | 1976-04-13 | — | — | US | disclosed |
| US-3950359-A | PROSTAGLANDINS AND METHODS OF MAKING SAME | MERCK & CO., INC. (US) | 1976-04-13 | — | — | US | disclosed |
| US-3925419-A | 5-Cyclic ethylene acetals of 5-oxocyclopentane heptanoic acids and esters | MERCK & CO INC | 1975-12-09 | — | — | US | disclosed |
| US-3894052-A | Cyclic ethylene acetals of 3-acetoxy-2-formyl-5-oxocyclopentaneheptanoic acid | MERCK & CO INC | 1975-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066647-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | CYP19A1 514/4885GRIN2B 3161/4885GRIN1 2859/4885 |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | AADAC, ENPP2, ATXN10 | CYP19A1 1170/4885GRIN2B 3271/4885GRIN1 3992/4885 |
| US-20200061063-A1 | BICYCLICALLY SUBSTITUTED URACILS AND THE USE THEREOF | UNG, UMPS, TYMP | CYP19A1 1787/4885GRIN2B 3441/4885GRIN1 3503/4885 |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | AADAC, ENPP2, ATXN10 | CYP19A1 1170/4885GRIN2B 3271/4885GRIN1 3992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.